The Economic Times Healthcare and Biotech News This is an RSS file. You can use it to subscribe to this data in your favourite RSS reader or to display this data on your own website or blog.

Budget 2024: Pharma industry seeks incentives for R&D, conducive policies
In the upcoming union budget 2024, the Indian pharmaceutical industry is seeking fiscal incentives to promote research and development (R&D) as it is expected to reach a market size of USD 400-450 billion by 2047. The Indian Pharmaceutical Alliance Secretary General, Sudarshan Jain, emphasized the need for continuous investments in research due to high risk and low success rates. The interim Budget 2024-25 should provide benefits in terms of direct and indirect taxes and facilitate business ease for pharma companies. (Source: The Economic Times Healthcare and Biotech News)
Source: The Economic Times Healthcare and Biotech News - January 14, 2024 Category: Pharmaceuticals Source Type: news

Govt says yet to take decision on roll-out of HPV vaccination against cervical cancer
The Union Health Ministry in India clarified that it has not yet made a decision regarding the rollout of the Human Papillomavirus (HPV) vaccination against cervical cancer in the country. Dismissing media reports speculating about a vaccination campaign in the second quarter of 2024 for girls aged 9-14, the ministry stated that such reports are untrue. (Source: The Economic Times Healthcare and Biotech News)
Source: The Economic Times Healthcare and Biotech News - January 13, 2024 Category: Pharmaceuticals Source Type: news

Central drug regulator cracks down on FDCs
In 2012, a parliamentary standing committee of the health ministry had observed in its report that some of the state licensing authorities issued manufacturing licences for a large number of FDCs without prior clearance from the central drug authority, resulting in the availability of several FDCs which were not tested for safety and efficacy. (Source: The Economic Times Healthcare and Biotech News)
Source: The Economic Times Healthcare and Biotech News - January 12, 2024 Category: Pharmaceuticals Source Type: news

Zydus Group to invest Rs 5,000 cr in Gujarat
Zydus Group plans to invest Rs 5,000 crore in Gujarat, including biotechnology products and hospitals. Memoranda of Understanding (MoUs) have been signed. Nayara Energy will expand its refinery at Vadinar and increase its retail network. Torrent Group will invest nearly Rs 48,000 crore in energy generation and distribution, including solar and hydel plants. Welspun Group will invest Rs 40,000 crore in the state over the next five years. (Source: The Economic Times Healthcare and Biotech News)
Source: The Economic Times Healthcare and Biotech News - January 12, 2024 Category: Pharmaceuticals Source Type: news

Beat Diabetes With Lifestyle Modification
(Source: The Economic Times Healthcare and Biotech News)
Source: The Economic Times Healthcare and Biotech News - January 11, 2024 Category: Pharmaceuticals Source Type: news

Diabetes, not a death sentence: These lifestyle modifications can help you live well
The dreaded ‘D’ word—diabetes—no longer carries the same weight as a life sentence. While traditional diabetes management relied solely on medications, there’s a growing emphasis on the pivotal role lifestyle changes can play in supporting and enhancing the well-being of individuals suffering from diabetes. In the second installment of the USV diabetes awareness multimedia series, titled ‘Beat Diabetes With Lifestyle Modification’, some of India’s leading endocrinologists convened to impart savvy and sustainable strategies for embracing transformative lifestyle shifts. (Source: The Economic Times Healthcare and Biotech News)
Source: The Economic Times Healthcare and Biotech News - January 11, 2024 Category: Pharmaceuticals Source Type: news

India could see drug shortages, price rise owing to new rule: Industry executives
A recent notification by the health ministry covers the revised Schedule M rules for good manufacturing practices and requirements of premises, plant and equipment for pharmaceutical products, with provisions for an annual product quality review as well as quality risk management and a pharmaceutical quality system. (Source: The Economic Times Healthcare and Biotech News)
Source: The Economic Times Healthcare and Biotech News - January 10, 2024 Category: Pharmaceuticals Source Type: news

Ozone Pharmaceuticals eyes Rs 1,000 crore topline in next 3 years
According to the statement, Ozone launched its Molecule initiative with a vision to become the world's foremost pain management company. (Source: The Economic Times Healthcare and Biotech News)
Source: The Economic Times Healthcare and Biotech News - January 10, 2024 Category: Pharmaceuticals Source Type: news

India to demand faster inspection of pharma firms by USFDA; raise export regulations at TPF on Friday
The Indian side will also raise the issue of reinstating the Generalized System of Preferences (GSP) status to India, the official said. (Source: The Economic Times Healthcare and Biotech News)
Source: The Economic Times Healthcare and Biotech News - January 10, 2024 Category: Pharmaceuticals Source Type: news

Akumentis Healthcare launches drug for treatment of epilepsy
"We understand the immense physical and emotional toll that frequent seizures can have on patients and their families," Akumentis Executive Director Kanishk Jain said. This is the driving force behind our commitment to developing novel solutions that effectively relieves the complexities of these disorders, he added. (Source: The Economic Times Healthcare and Biotech News)
Source: The Economic Times Healthcare and Biotech News - January 10, 2024 Category: Pharmaceuticals Source Type: news

Lupin introduces generic product in US market
Drug firm Lupin on Wednesday said it has launched a product, used as an aid to smoking cessation treatment, in the US market. The company has launched Varenicline tablets in strengths of 0.5 mg and 1 mg, after having received approval from the US Food and Drug Administration (USFDA), the Mumbai-based drug maker said in a regulatory filing. (Source: The Economic Times Healthcare and Biotech News)
Source: The Economic Times Healthcare and Biotech News - January 10, 2024 Category: Pharmaceuticals Source Type: news

Indian pharma market grows over 9 per cent in December
Among the top therapies, cardiac, anti-infectives and neuro/central nervous system have shown a relatively stronger volume growth last month, according to data from research firm PharmaTrac. Antibiotic drug Augmentin and anti-diabetes Glycomet GP continued to be the top-selling medicine brands. (Source: The Economic Times Healthcare and Biotech News)
Source: The Economic Times Healthcare and Biotech News - January 9, 2024 Category: Pharmaceuticals Source Type: news

Dr Reddy's recalls over 8,000 bottles of generic drug in US due to packaging error
Dr Reddy's Laboratories is recalling over 8,000 bottles of Tacrolimus capsules from the US market due to a packaging error. The Hyderabad-based drug major has already recalled 4,000 bottles of the same medication in March 2023. The recall is a Class II recall, initiated on December 15, 2023, due to potential adverse health consequences or a low probability of serious adverse health effects. (Source: The Economic Times Healthcare and Biotech News)
Source: The Economic Times Healthcare and Biotech News - January 7, 2024 Category: Pharmaceuticals Source Type: news

Government orders new drug-making standards after overseas deaths
The Indian government has issued a notification requiring pharmaceutical companies to adhere to new manufacturing standards in response to concerns over the quality and safety of drugs. The move comes in the wake of overseas deaths linked to Indian-made drugs since 2022, prompting increased scrutiny of the $50 billion pharmaceutical industry. (Source: The Economic Times Healthcare and Biotech News)
Source: The Economic Times Healthcare and Biotech News - January 6, 2024 Category: Pharmaceuticals Source Type: news

Quadria in talks to buy into dialysis chain NephroPlus
Quadria Capital, an Asia-focused private equity fund, is in talks to acquire a significant minority stake in India's largest dialysis chain, NephroPlus, valued at ₹2,000 crore ($250 million). Existing investors, Bessemer Venture Partners and International Finance Corporation, will exit by selling a 30% stake together, while Investcorp is likely to sell a small stake. NephroPlus, founded in 2009, operates 300+ dialysis centres in over 180 cities across four countries. (Source: The Economic Times Healthcare and Biotech News)
Source: The Economic Times Healthcare and Biotech News - January 4, 2024 Category: Pharmaceuticals Source Type: news